{"id":"W4200303884","doi":"10.51731/cjht.2021.152","title":"Encorafenib (Braftovi)","year":2021,"lang":"en","type":"article","venue":"Canadian Journal of Health Technologies","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"","keywords":"Reimbursement; Medicine; Cetuximab; Drug class; Drug; Family medicine; Business; Pharmacology; Economic growth; Internal medicine; Economics; Cancer; Health care","routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002827688,0.0002534689,0.0002351123,0.0007257025,0.0001943719,0.0004655689,0.0001704227,0.0002459557,0.005644975],"category_scores_gemma":[0.0003706965,0.00005468369,0.000263504,0.000590593,0.0001268965,0.0002311996,0.0001470462,0.0002980124,0.0007795358],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001585379,"about_ca_system_score_gemma":0.001287886,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.01625172,"about_ca_topic_score_gemma":0.1021363,"domain_scores_codex":[0.9998399,0.00002489429,0.00001239696,0.000020417,0.00007983262,0.00002247127],"domain_scores_gemma":[0.9998666,0.00002185669,0.0000369697,0.000004016551,0.00005222331,0.00001833665],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0007208248,0.0001026055,0.002593715,0.003114514,0.000222049,0.000297911,0.00003264798,0.0004676023,0.01456383,0.001717936,0.022203,0.9539635],"study_design_scores_gemma":[0.00035474,0.001704035,0.02482924,0.001589132,0.0004275253,0.003274814,0.0001100847,0.0003702831,0.02197237,0.0005499132,0.9447883,0.00002973316],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"other","genre_scores_codex":[0.06140162,0.8622086,0.001255569,0.002862123,0.000389436,0.0002008763,0.003069015,0.0001592447,0.06845351],"genre_scores_gemma":[0.4113995,0.523621,0.003024797,0.002477541,0.0001884421,0.0001301753,0.003839671,0.00002283535,0.0552961],"genre_candidate":"other","genre_consensus":null,"teacher_disagreement_score":0.01625172,"threshold_uncertainty_score":0.03231424,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01682635852450084,"score_gpt":0.2447189312474354,"score_spread":0.2278925727229345,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}